NeutraKine®VEGF165/121 Monoclonal antibody
NeutraKine®VEGF165/121 Monoclonal Antibody for Neutralization, ELISA
Host / Isotype
Mouse / IgG1
Cat no : 69025-1-Ig
69025-1-Ig targets NeutraKine®VEGF165/121 in Neutralization, ELISA applications and shows reactivity with Human samples.
|Host / Isotype||Mouse / IgG1|
|Immunogen||human HumankineVEGF165/121 protein HZ-1038|
|Full Name||vascular endothelial growth factor A|
|Gene ID (NCBI)||7422|
|Purification Method||Protein G purification|
|Storage Buffer||Sterile PBS.|
|Reconstitution||This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.|
|Stability and Storage||Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.|
VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are associated with microvascular complications of diabetes type 1 (MVCD1). VEGFA has 17 isoforms with MW from 16 to 45 kDa. Some isoforms have homodimer forms (e.g.; VEGFA189 38 kDa or VEFGA110 34 kDa). VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids (PMID:15602010 ).
This antibody is used to neutralize the bioactivity of VEGF165/121. ELISA test suggests that this antibody recognize VEGF165 and VEGF121. According to sequence similarity, it may recognize other isoforms.